Clinical Trials
- Brain, Spinal Cord & Nervous System
AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- Brain, Spinal Cord & Nervous System
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS)
- Ages18 years - 55 years
- GenderBoth
- Brain, Spinal Cord & Nervous System
Identifying and Characterizing Preclinical MS
- Ages13 years and older
- GenderBoth